NeoGenomics, Inc. (NASDAQ:NEO) VP Jennifer Balliet sold 6,833 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $23.45, for a total value of $160,233.85. Following the transaction, the vice president now owns 29,529 shares of the company’s stock, valued at $692,455.05. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
NEO traded up $0.39 during mid-day trading on Monday, hitting $24.46. 16,233 shares of the stock were exchanged, compared to its average volume of 668,545. The firm’s fifty day moving average is $20.90 and its two-hundred day moving average is $22.61. NeoGenomics, Inc. has a 1-year low of $11.05 and a 1-year high of $26.89. The company has a current ratio of 4.24, a quick ratio of 4.05 and a debt-to-equity ratio of 0.24. The company has a market cap of $2.45 billion, a PE ratio of 188.38 and a beta of 0.94.
NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, October 29th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.01. NeoGenomics had a return on equity of 4.60% and a net margin of 0.55%. The firm had revenue of $104.70 million for the quarter, compared to analyst estimates of $99.38 million. During the same quarter in the prior year, the company earned $0.05 EPS. NeoGenomics’s revenue was up 51.5% on a year-over-year basis. As a group, research analysts anticipate that NeoGenomics, Inc. will post 0.19 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of NeoGenomics by 41.6% during the 2nd quarter. Vanguard Group Inc. now owns 8,173,714 shares of the medical research company’s stock worth $179,331,000 after acquiring an additional 2,401,227 shares in the last quarter. Marshall Wace LLP raised its position in shares of NeoGenomics by 492.5% during the 2nd quarter. Marshall Wace LLP now owns 1,358,313 shares of the medical research company’s stock worth $29,801,000 after acquiring an additional 1,129,043 shares in the last quarter. BlackRock Inc. raised its position in shares of NeoGenomics by 8.0% during the 2nd quarter. BlackRock Inc. now owns 14,925,327 shares of the medical research company’s stock worth $327,462,000 after acquiring an additional 1,100,263 shares in the last quarter. Nuveen Asset Management LLC acquired a new stake in shares of NeoGenomics during the 2nd quarter worth about $19,966,000. Finally, Wells Fargo & Company MN raised its position in shares of NeoGenomics by 122.4% during the 2nd quarter. Wells Fargo & Company MN now owns 532,393 shares of the medical research company’s stock worth $11,680,000 after acquiring an additional 293,049 shares in the last quarter. 84.83% of the stock is currently owned by institutional investors.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.